New Research Reveals Phelan-McDermid Syndrome Is Far More Common Than Previously Believed, Affecting 1 in 7,300 People

Recent scientific investigations spearheaded by researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai have fundamentally shifted the medical community’s understanding of Phelan-McDermid syndrome (PMS). Published in the peer-reviewed journal Autism Research, the landmark study indicates that this rare genetic disorder occurs at a significantly higher frequency than historical medical literature suggested. According to the updated epidemiological calculations, PMS affects approximately 1 in every 7,300 individuals, pointing to a much larger patient population than previously recognized and carrying profound implications for healthcare providers, genetic counselors, pharmaceutical developers, and affected families worldwide.

Phelan-McDermid syndrome is a complex genetic condition primarily driven by a deletion, microdeletion, or point mutation involving the SHANK3 gene, located on the long arm of chromosome 22 (22q13.33). The SHANK3 gene plays a critical role in neurodevelopment by encoding a master scaffold protein localized in the postsynaptic density of excitatory synapses. This protein is essential for proper neuronal communication, synaptic plasticity, and structural brain formation. When the gene is mutated or missing, it triggers a cascade of neurodevelopmental disruptions, leading to a remarkably broad and heterogeneous spectrum of clinical manifestations.

Individuals diagnosed with PMS typically experience a wide array of medical, intellectual, and behavioral challenges. These frequently include global developmental delays, severe speech impairments or complete absence of verbal communication, hypotonia (low muscle tone), motor dysfunctions, sleep disturbances, gastrointestinal issues, and epilepsy. Furthermore, a substantial majority of individuals diagnosed with PMS also meet the clinical criteria for autism spectrum disorder (ASD). In fact, genetic alterations affecting the SHANK3 gene alone are estimated to account for roughly one percent of all diagnosed cases of autism spectrum disorder globally, cementing its status as one of the most prominent single-gene causes of autism.

Unveiling the Hidden Population Through Vast Genetic Datasets

For decades, determining the true prevalence of rare genetic disorders like Phelan-McDermid syndrome has posed a monumental challenge for epidemiologists and geneticists. Earlier prevalence figures were largely derived from clinical registries of patients who had already received a formal diagnosis, inherently creating a skewed sample that missed undiagnosed or mildly affected individuals.

To overcome these historical limitations and establish a more accurate statistical baseline, researchers at Mount Sinai embarked on a massive collaborative data-mining initiative. The investigative team partnered with prominent commercial genetic testing laboratories, major academic medical centers, and leading autism research programs. By pooling their resources, the researchers were able to examine and cross-reference genetic testing data from nearly 180,000 individuals with autism who had undergone comprehensive clinical or research-grade genetic sequencing.

The breadth of this analysis was unprecedented in PMS research, combining data drawn from ten distinct and reputable sources. These included commercial genetic testing pioneers such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale genomic research initiatives like the SPARK (Simons Foundation Powering Autism Research for Knowledge) study, the Autism Sequencing Consortium, and several top-tier pediatric children’s hospitals across the United States.

By analyzing this vast genomic repository, the research team identified individuals carrying pathogenic variants or deletions of the SHANK3 gene. Crucially, the investigators did not stop at a raw numerical count. They applied sophisticated statistical corrections to account for persistent diagnostic blind spots, including undiagnosed cases within marginalized communities, historical limitations in standard clinical genetic testing panels, and individuals with Phelan-McDermid syndrome whose clinical presentations do not manifest as classic autism spectrum disorder and who therefore might have slipped through autism-centric screening initiatives.

Through this rigorous methodological framework, the researchers arrived at a striking new prevalence estimate: 13.7 cases per 100,000 people. When converted, this statistic reveals that roughly 1 in 7,300 individuals is living with Phelan-McDermid syndrome. Applied to the general population of the United States alone, this figure suggests that upwards of 45,000 individuals may be affected—a dramatic upward revision from historical estimates that counted diagnosed cases in the low thousands.

The Diagnostic Gap: Why Thousands Remain Unidentified

The stark discrepancy between the number of officially diagnosed PMS patients and the newly calculated prevalence figures highlights a systemic healthcare challenge: thousands of individuals live their lives without knowing the genetic root cause of their developmental challenges.

Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the research paper, emphasized the structural barriers that contribute to this diagnostic vacuum.

"The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy explained. "Furthermore, families may face significant insurance and financial barriers, or they may receive routine clinical tests that do not adequately evaluate the SHANK3 gene or fail to detect microdeletions."

In many clinical settings, standard diagnostic workups for developmental delays stop short of comprehensive chromosomal microarray analysis or full exome/genome sequencing. Consequently, children presenting with global developmental delays or behavioral challenges may receive a descriptive label such as developmental delay or idiopathic autism without physicians uncovering the specific underlying molecular etiology. This lack of precision leaves families navigating a complex medical landscape without a clear understanding of what to expect as their child matures.

The Chronology of PMS Research and Awareness

The journey toward understanding Phelan-McDermid syndrome spans less than three decades, making it a relatively young field in modern medical genetics.

• 1990s: Researchers first began to systematically map the terminal region of the long arm of chromosome 22, noting that deletions in this specific region were associated with hypotonia, developmental delay, and absent speech. The syndrome was initially designated as 22q13 deletion syndrome.
• 2001: Dr. Katy Phelan, a cytogeneticist, and her clinical colleagues published landmark case descriptions that solidified the clinical phenotype of the disorder. In recognition of her foundational work alongside Dr. María McDermid, the condition was formally named Phelan-McDermid syndrome.
• 2006: Scientific focus sharply narrowed onto the SHANK3 gene as the primary critical region responsible for the neurological and behavioral manifestations of PMS. This discovery bridged the gap between rare chromosomal disorders and idiopathic autism research.
• 2010s: Advocacy groups, most notably CureSHANK and the Phelan-McDermid Syndrome Foundation, were established by dedicated families and clinicians. These organizations catalyzed patient registries, natural history studies, and fundraising efforts to push basic laboratory science toward translational clinical trials.
• Present Day: The publication of the Mount Sinai prevalence study marks a major milestone, shifting PMS from an ultra-rare orphan condition into a more broadly recognized neurodevelopmental disorder. This epidemiological shift coincides precisely with the arrival of precision medicine clinical trials targeting the synaptic biology of the SHANK3 pathway.

The Imperative of Comprehensive Genetic Testing

In light of their findings, the Mount Sinai research team and their collaborators are issuing a strong call to action for the broader medical and pediatric communities: universal genetic testing for children presenting with neurodevelopmental concerns.

Dr. Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, co-founder of the Autism Sequencing Consortium, and senior author of the study, underscored the transformative value of genetic knowledge for patients and their families.

"We recommend that every child with autism undergo genetic testing, because knowledge is power," Dr. Buxbaum stated. "These precise genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming directly from these genetic discoveries."

This sentiment is echoed by corporate and philanthropic partners who supported the research. The study was financially backed and made possible through collaborative efforts involving CureSHANK and Neuren Pharmaceuticals, highlighting a growing synergy between academic research institutions and industry developers dedicated to rare disease therapeutics.

Dr. Rachel Groth, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, elaborated on the ethical and practical urgency driving these epidemiological efforts.

"Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative," Dr. Groth noted. "Patients cannot benefit from these medical advances if they never receive a diagnosis."

Clinical Trials and the Promise of Precision Medicine

The timing of the Mount Sinai prevalence study is particularly critical. For many years, a diagnosis of Phelan-McDermid syndrome offered little more than an explanation for symptoms, with medical management focusing entirely on symptomatic relief—such as physical therapy, speech therapy, and behavioral interventions. However, advancements in neuroscience and molecular biology have ushered in an era of precision medicine that seeks to correct or compensate for the underlying cellular defects caused by SHANK3 mutations.

Currently, several clinical trials are underway or entering advanced planning stages, evaluating targeted pharmacological interventions designed to restore synaptic function, improve communication pathways, and enhance cognitive flexibility in patients with PMS. Because these targeted therapies interact directly with the biochemical pathways governed by the SHANK3 protein, identifying patients with specific genetic mutations is a strict prerequisite for trial enrollment and eventual therapeutic administration.

For families, securing a genetic diagnosis has evolved from an academic exercise into a practical gateway for survival and support. A confirmed diagnosis grants families entry into specialized medical surveillance protocols (such as routine renal and cardiac evaluations, which are sometimes recommended for PMS patients), connects them with robust patient advocacy networks, and opens doors to cutting-edge clinical trials that could fundamentally alter the trajectory of the disease.

Geraldine Bliss, Board Chair of CureSHANK, reflected on the profound emotional and practical validation the study provides to the community of families living with the disorder.

"This study confirms what many families, clinicians, and advocates have suspected for years," Bliss said. "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."

Broader Impact and Future Directions

The implications of the Mount Sinai study extend far beyond the immediate confines of Phelan-McDermid syndrome research. By establishing a robust methodology for uncovering hidden prevalence rates in rare genetic disorders, the study serves as a blueprint for investigating other single-gene conditions associated with autism and intellectual disability.

Furthermore, the findings reinforce ongoing public health initiatives such as "Start Genetic," a global awareness campaign championed by CureSHANK and supported by international medical alliances. This campaign actively encourages physicians, pediatricians, healthcare systems, patients, and advocacy groups to adopt a "think genetic first" philosophy when evaluating children with unexplained developmental delays, intellectual disabilities, or autism spectrum disorder.

As the medical community digests these new prevalence numbers, the central challenge shifts from discovery to implementation. Healthcare infrastructure must adapt to make comprehensive genetic testing accessible, affordable, and universally integrated into pediatric neurology and developmental pediatrician workflows. Only by bridging the gap between genomic technology and clinical practice can healthcare systems ensure that all individuals living with Phelan-McDermid syndrome are identified, supported, and positioned to benefit from the next generation of life-changing therapeutic breakthroughs.